These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 2216467

  • 1. Mapping of the functional domains of the v-rel oncogene.
    Garson K, Kang CY.
    Oncogene; 1990 Sep; 5(9):1431-4. PubMed ID: 2216467
    [Abstract] [Full Text] [Related]

  • 2. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
    Morrison LE, Boehmelt G, Enrietto PJ.
    Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
    [Abstract] [Full Text] [Related]

  • 3. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T.
    Bhat GV, Temin HM.
    Oncogene; 1990 May; 5(5):625-34. PubMed ID: 2189101
    [Abstract] [Full Text] [Related]

  • 4. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G, Gilmore TD.
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [Abstract] [Full Text] [Related]

  • 5. The role of the carboxy terminus of v-Rel in transformation and activation of endogenous gene expression.
    Smardova J, Walker A, Morrison LE, Kabrun N, Enrietto PJ.
    Oncogene; 1995 May 18; 10(10):2017-26. PubMed ID: 7761102
    [Abstract] [Full Text] [Related]

  • 6. Selective activation of the proto-oncogene c-jun promoter by the transforming protein v-Rel.
    Fujii M, Minamino T, Nomura M, Miyamoto KI, Tanaka J, Seiki M.
    Oncogene; 1996 May 16; 12(10):2193-202. PubMed ID: 8668346
    [Abstract] [Full Text] [Related]

  • 7. Identification of v-Rel oncogene-induced inhibitor of apoptosis by differential display.
    You M, Bose HR.
    Methods; 1998 Dec 16; 16(4):373-85. PubMed ID: 10049645
    [Abstract] [Full Text] [Related]

  • 8. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters.
    Gélinas C, Temin HM.
    Oncogene; 1988 Oct 16; 3(4):349-55. PubMed ID: 2856247
    [Abstract] [Full Text] [Related]

  • 9. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
    Sif S, Capobianco AJ, Gilmore TD.
    Oncogene; 1993 Sep 16; 8(9):2501-9. PubMed ID: 8361761
    [Abstract] [Full Text] [Related]

  • 10. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
    Sarkar S, Gilmore TD.
    Oncogene; 1993 Aug 16; 8(8):2245-52. PubMed ID: 8336947
    [Abstract] [Full Text] [Related]

  • 11. Characterization of changes in gene expression associated with malignant transformation by the NF-kappaB family member, v-Rel.
    Petrenko O, Ischenko I, Enrietto PJ.
    Oncogene; 1997 Oct 02; 15(14):1671-80. PubMed ID: 9349500
    [Abstract] [Full Text] [Related]

  • 12. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
    Epinat JC, Dvorin EL, Gilmore TD.
    Oncogene; 2000 Jun 29; 19(28):3131-7. PubMed ID: 10918567
    [Abstract] [Full Text] [Related]

  • 13. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
    Starczynowski DT, Reynolds JG, Gilmore TD.
    Oncogene; 2005 Nov 10; 24(49):7355-68. PubMed ID: 16027730
    [Abstract] [Full Text] [Related]

  • 14. The suppression of SH3BGRL is important for v-Rel-mediated transformation.
    Majid SM, Liss AS, You M, Bose HR.
    Oncogene; 2006 Feb 02; 25(5):756-68. PubMed ID: 16186799
    [Abstract] [Full Text] [Related]

  • 15. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
    Carrasco D, Rizzo CA, Dorfman K, Bravo R.
    EMBO J; 1996 Jul 15; 15(14):3640-50. PubMed ID: 8670867
    [Abstract] [Full Text] [Related]

  • 16. The activation of TC10, a Rho small GTPase, contributes to v-Rel-mediated transformation.
    Tong S, Liss AS, You M, Bose HR.
    Oncogene; 2007 Apr 05; 26(16):2318-29. PubMed ID: 17016434
    [Abstract] [Full Text] [Related]

  • 17. The N-terminal env-derived amino acids of v-rel are required for full transforming activity.
    Garson K, Percival H, Kang CY.
    Virology; 1990 Jul 05; 177(1):106-15. PubMed ID: 2162102
    [Abstract] [Full Text] [Related]

  • 18. Avian reticuloendotheliosis virus-transformed lymphoid cells contain multiple pp59v-rel complexes.
    Davis N, Bargmann W, Lim MY, Bose H.
    J Virol; 1990 Feb 05; 64(2):584-91. PubMed ID: 2153225
    [Abstract] [Full Text] [Related]

  • 19. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
    Nehyba J, Hrdlicková R, Bose HR.
    Oncogene; 1997 Jun 19; 14(24):2881-97. PubMed ID: 9205096
    [Abstract] [Full Text] [Related]

  • 20. The v-rel oncogene product is complexed with cellular proteins including its proto-oncogene product and heat shock protein 70.
    Lim MY, Davis N, Zhang JY, Bose HR.
    Virology; 1990 Mar 19; 175(1):149-60. PubMed ID: 2155506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.